Efficacy and Safety of Glucagon-Like Peptide 1 Receptor Agonists in Parkinson Disease: A Systematic Review and Meta-Analysis - PubMed
3 hours ago
- #Parkinson's disease
- #GLP-1 receptor agonists
- #meta-analysis
- GLP-1 receptor agonists (GLP-1RAs) were evaluated for efficacy and safety in Parkinson's disease (PD) patients.
- No significant improvement was found in motor symptoms (MDS-UPDRS Part III scores) either off or on medication.
- Secondary outcomes also showed no significant benefits with GLP-1RA use.
- GLP-1RAs were associated with increased gastrointestinal side effects, including nausea, vomiting, constipation, and weight loss.
- Current evidence does not support a statistically significant overall benefit of GLP-1RAs in PD, but more trials are needed to explore their potential.